Text and Data Mining valid from 2019-05-29
Received: 29 January 2019
Accepted: 17 May 2019
First Online: 29 May 2019
Ethics approval and consent to participate
: Not applicable.
: A. Zaremba received travel support from Novartis and Bristol-Myers Squibb.E. Chorti received travel support from Bristol-Myers Squibb, MSD SHARP & DOHME and Novartis.F. Jockenhöfer declares that she has no conflicts of interest.S. Bolz declares that she has no conflicts of interest.S. Sirin declares that she has no conflicts of interest.M. Glas reports a Consulting / advisory role to Roche, Novartis, Daiichi Sankyo, Novocure and travel support from Medac and Novocure. Furthermore he received Honoraria from Novartis, Merck, Novocure, Medac, and Kyowa Kirin.J.C.Becker has received speaker honoraria from Amgen, MerckSerono, Pfizer, and Sanofi; he has received advisory board honoraria from Amgen, CureVac, eTheRNA, Laser, Analytica, Lytix, MerckSerono, Novartis, Rigontec, Takeda and Sanofi; and he has received research funding from Alcedis, Amgen, Boehringer Ingelheim, BMS and MerckSerono. J.C.Becker’s activities with Bristol-Myers Squibb, MerckSerono and Pfizer are related to the submitted report (therapy of advanced MCC).S. Ugurel declares advisory board and speakers honoraria from Bristol-Myers-Squibb, Merck Sharp& Dohme and Roche, as well as grant and travel support from Bristol-Myers-Squibb, Merck Sharp & Dohme, Roche und medac.A. Roesch reports non-financial support from Amgen, non-financial support from Roche, non-financial support and personal fees from Merck/MSD, non-financial support and grants from Novartis, non-financial support and grants from BMS, non-financial support from TEVA and grants from Adtec.D. Schadendorf reports personal fees, adboards and patient’s fees from Pierre Fabre, personal fees from Amgen, personal fees from Boehringer Ingelheim, personal fees from Leo Pharma, personal fees and patients’ fees from Roche, personal fees and patients’ fees from MSD, personal fees from Incyte, personal fees and patients’ fees from Regeneron, personal fees from 4SC, personal fees from AstraZeneca, grants, personal fees and patients’ fees from BMS, personal fees and patients’ fees from Merck-EMD, personal fees from Pfizer, personal fees and patients’ fees from Philiogen, and personal fees from Array.E. Livingstone has had intermittent advisory board relationships with Roche, BMS, Novartis and Actelion and has received travel grants and honoraria from Roche, BMS, MSD, Amgen, Novartis, Boehringer-Ingelheim, medac.T. Hagenacker has received honoraria and travel reimbursement from Alexion, CSL Behring, Novartis, Biogen, Pfizer.L. Zimmer has served as consultant or/and has received honoraria from Roche, Bristol-Myers Squibb (BMS), Merck Sharp& Dohme (MSD), Novartis, Merck, Sanofi, Pierre Fabre and travel support from MSD, BMS, Amgen, Pierre Fabre and Novartis.